免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展  

Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome

作　　者：张若曦 韩冰[1] ZHANG Ruo-xi;HAN Bing(Department of Hematology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院血液科,北京100730

出　　处：《基础医学与临床》2021年第8期1210-1215,共6页Basic and Clinical Medicine

基　　金：北京自然科学基金(7192168);中国医学科学院医学创新基金(2016-I2M-3-004);中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2020)。

摘　　要：免疫检查点抑制剂(ICI)通过抑制肿瘤细胞逃逸、增强免疫应答而作为MDS潜在的治疗方式,本文回顾性分析了针对PD-1/PD-L1和CTLA-4的ICI治疗MDS的临床试验,分析了ICI治疗的疗效和不良反应。ICI单药或与去甲基化药物(HMA)合用是可耐受的。尽管目前单药ICI治疗的疗效有限,但和HMA可能具有协同作用,且对于HMA无效患者可作为一种潜在的选择。尽管存在免疫相关不良反应(irAEs),但多数可通过类固醇逆转。Immune checkpoint inhibitor(ICI)is a potential treatment for MDS by inhibiting the escape of tumor cells and enhancing immune responses.This article reviewed the efficacy and adverse events of clinical trials focusing on PD-1/PD-L1 and CTLA-4 inhibitors on MDS patients.Although the efficacy of single-agent ICI therapy was limited,it may have a synergistic effect with hypomethylation agent(HMA),which could be a choice for patients who fail to respond to HMA treatment.Immune-related adverse events(irAE)were observed,but most can be reversed by steroids.

关 键 词：免疫检查点抑制剂 骨髓异常增生综合征 疗效 安全性 

分 类 号：R551[医药卫生—血液循环系统疾病]